BUZZ - As Eli Lilly expands access to weight loss drugs through its platform, “Hims & Hers” is emerging

November 6 - ** The stock price of telemedicine platform Hims & Hers Health (HIMS.N) rose 7.6% in pre-market trading to $25.88

** Reportedly, according to a new agreement, Eli Lilly (LLY.N)'s weight loss drugs Zepbound and Foundayo will be available through the Hims & Hers platform

** Eligible patients who are prescribed by providers on the platform can access Eli Lilly's self-pay prices without leaving the Hims & Hers platform

** Eli Lilly's Zepbound injectable weight loss drug starts at $299 per month, while the oral weight loss drug Foundayo starts at $149 per month

** Hims & Hers stated that patients can complete consultations on the platform, obtain prescriptions when appropriate, and have FDA-approved Eli Lilly medicines shipped directly to their homes

** Hims stated that the company has never offered compounded generic versions of Eli Lilly's GLP-1 class weight loss drugs, and promises it will not do so in the future

** As of the close of the previous trading day, the stock had fallen about 26% year-to-date

(To assist non-native English speakers, Reuters provides automated translations of its reports into several other languages. As automated translations may contain errors or lack required context, Reuters does not guarantee the accuracy of these automated texts and provides them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss resulting from the use of automated translation features.)